Aethlon Medical, Inc. Announces Annual Meeti...(c and therapeutic device solutions for i...)

Date:9/16/2009

c and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

Forward-looking Statements

This release contains forward-looking statements which reflect management's current views of future events and operations including but not limited to estimates of financial performance and cash flows, trends in subscriber preference and engagement and results of marketing strategies. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include the risk of changing economic conditions, the impact of executive management transitions, failure of product demand or market acceptance of both existing and new products and services and the impact of competitive products and pricing. Please see Aethlon Medical, Inc.'s recent filings with the Securities and Exchange Commission for information about these and other risks that may affect the Company. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements speak only as of the date hereof, and Aethlon Medical, Inc. does not undertake to publicly update or revise any of its forward-looking statements, even if experience or future changes show that the indicated results or events will not be realized.

<
'/>"/>

SOURCE Aethlon Medical, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
2. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
3. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
4. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. China Sky One Medical, Inc. Appoints New Independent Director
7. Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries
8. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
9. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
10. China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program
11. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results